November 15, 2002

Federal Court Ruling Impacts FDA Suppression Of Medical Speech

Issues:

Economic and Individual Liberties: Commercial Speech

By George W. Evans, an Associate General Counsel, Pfizer Inc., and General Counsel, Pfizer Pharmaceuticals Group, and Arnold I. Friede, a Senior Corporate Counsel at Pfizer Inc., who formerly served in the FDA Chief Counsel’s Office.

Related Content

Legal Backgrounders

October 4, 2002

FDA Limits On Print Drug Ads Violate The First Amendment

By Richard L. Frank, a principal, and Tish Eggleston Pahl, a senior associate, at the Washington, D.C. law firm Olsson, Frank and Weeda, P.C.

Legal Backgrounders

August 23, 2002

An FDA Q&A: How Does The First Amendment Limit Its Regulatory Power?

By Alan R. Bennett, a partner in the Washington, D.C. office of the law firm Ropes & Gray, and Kenneth P. Berkowitz, President of KPB Associates, a Washington, D.C. consulting firm specializing in the regulation of medical communications.

Legal Opinion Letters

September 17, 1999

Court Again Nullifies FDA Policies Restricting Health Care Information

By George M. Burditt, a partner with the Chicago law firm Bell, Boyd & Lloyd.

Legal Opinion Letters

November 4, 1998

Court Suppresses FDA Censorship Of Health Product Information

By George M. Burditt

In Op-Ed, WLF Advisory Board Member Questions FDA “Crackdown” on Pharma Ads

National Retail Federation v. James

A Threat to M&A Market Vitality: “Break-Up Fee” Taxation in the Pending Appeal of AbbVie v. Comm. of Internal Revenue

Legal Opinion Letters

Federal Court Ruling Impacts FDA Suppression Of Medical Speech

FDA Limits On Print Drug Ads Violate The First Amendment

An FDA Q&A: How Does The First Amendment Limit Its Regulatory Power?

Court Again Nullifies FDA Policies Restricting Health Care Information

Court Suppresses FDA Censorship Of Health Product Information

Featured

In Op-Ed, WLF Advisory Board Member Questions FDA “Crackdown” on Pharma Ads

Featured Case

National Retail Federation v. James

Featured

A Threat to M&A Market Vitality: “Break-Up Fee” Taxation in the Pending Appeal of AbbVie v. Comm. of Internal Revenue

Legal Opinion Letters

Federal Court Ruling Impacts FDA Suppression Of Medical Speech

Related Content

FDA Limits On Print Drug Ads Violate The First Amendment

An FDA Q&A: How Does The First Amendment Limit Its Regulatory Power?

Court Again Nullifies FDA Policies Restricting Health Care Information

Court Suppresses FDA Censorship Of Health Product Information